Monfrini Edoardo, Di Fonzo Alessio
IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Adv Neurobiol. 2017;14:3-30. doi: 10.1007/978-3-319-49969-7_1.
The discovery of LRRK2 mutations as a cause of Parkinson's disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.
LRRK2突变作为帕金森病(PD)的病因被发现,包括散发性晚发型PD,这确立了遗传学在PD研究领域的决定性作用。在LRRK2突变中,G2019S突变大多存在于一个起源于中东共同祖先的单倍型中,已在全球不同人群中被发现。G2385R和R1628P变异体是亚洲人群中已被证实的PD风险因素。在此,我们详细描述LRRK2突变的起源、目前的全球流行病学情况以及外显率。此外,本章旨在描述LRRK2的其他明确/可能致病突变和风险变异体。最后,我们提供了一些关于LRRK2基因检测和咨询的一般指导原则。总之,LRRK2的发现彻底改变了对PD病因的理解,并为PD研究中遗传学的光明未来奠定了基础。